期刊
ONCOLOGIST
卷 16, 期 12, 页码 1784-1792出版社
OXFORD UNIV PRESS
DOI: 10.1634/theoncologist.2011-0169
关键词
Cancer control; Smoking; Symptom management; Symptom burden
类别
资金
- Tempur-Pedic Corporation
- National Institutes of Health [1R25-CA102618-01A1, 5KL2 RR024136-05]
- Ameritox
- Archimedes Pharmaceuticals
- Cephalon
- Covidien Mallinckrodt Inc.
- Endo Pharmaceuticals
- Forest Labs
- Meda Pharmaceuticals
- Ortho-McNeil Janssen Scientific Affairs LLD
- Otsuka Pharma
- Purdue Pharma
Background. Cigarette smoking has long been implicated in cancer development and survival. However, few studies have investigated the impact of smoking on symptom burden in cancer survivors during treatment and at survivorship stage. This study examines the influence of cigarette smoking on side effects among 947 cancer patients during and 6 months following treatment. Methods. Patients diagnosed with cancer and scheduled to receive chemotherapy and/or radiation therapy reported on current smoking status (yes, no) and total symptom burden [the sum of 12 common symptoms (fatigue, hair loss, memory, nausea, depression, sleep, pain, concentration, hot flashes, weight loss, skin problems, and dyspnea) scored on an 11-point scale ranging from 0 = not present to 10 = as bad as you can imagine] during treatment and at 6-month follow-up. The adjusted mean total symptom burden by smoking status was determined by analysis of covariance controlling for age, gender, race, education, occupation, treatment, cancer site, and Karnofsky performance score. Results. During treatment, smokers (S) had a significantly higher total symptom burden than nonsmokers (NS) (S = 46.3 vs. NS = 41.2; p < 0.05). At 6-month follow-up, smokers continued to report a higher total symptom burden than nonsmokers (S = 27.7 vs. NS = 21.9; p < 0.05). Participants who quit smoking before treatment levels had a total symptom burden similar to nonsmokers. Conclusion. Smoking was associated with an increased symptom burden during and following treatments for cancer. Targeted cessation efforts for smokers to decrease symptom burden may limit the likelihood of treatment interruptions and increase quality of life following treatment. The Oncologist 2011;16:1784-1792
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据